BEVESPI® is the commercial brand name of Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol, a fixed-dose dual bronchodilator combining a long-acting muscarinic antagonist and a long-acting β₂ agonist developed by AstraZeneca. It delivers sustained bronchodilation by acting on different airway receptors to relieve persistent bronchoconstriction.
Main Indications
Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Clinical Research
Global multicenter phase III trials demonstrated that this dual bronchodilator combination improves lung function and reduces dyspnea compared with single-agent long-acting bronchodilators;
Clinical studies in Asian subjects confirmed stable therapeutic efficacy and consistent safety profiles with global trial populations;
Long-term follow-up research verified sustained control of respiratory symptoms and lowered risk of COPD exacerbations during continuous treatment.
Common Side Effects
Severe but important risks: Paradoxical bronchospasm, severe hypersensitivity reactions, urinary retention and glaucoma;
Common mild adverse reactions: Headache, dry mouth, palpitations, nasopharyngitis, cough and muscle spasms.
Approval Status in China
Original drug BEVESPI® (Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol) was officially approved for marketing in China in 2019. It is currently a prescription inhaled medicine for chronic obstructive pulmonary disease.
Buy BEVESPI (Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
